No excess mortality risk for 10-­years survivors after high dose therapy with autologous stem cell transplantation (HDT‐ASCT) for relapsed/refractory Hodgkin's lymphoma (HL)

No excess mortality risk for 10-years survivors after high dose therapy with autologous stem cell transplantation (HDT‐ASCT) for relapsed/refractory Hodgkin's lymphoma (HL)

Published in 2014 by Knut Bjøro Smeland, Cecilie E. Kiserud, Jon Håvard Loge, Arne Kolstad, Alexander Fosså, Unn Merete Fagerli, Ragnhild Sørum Falk, Grete F. Lauritzsen, Oystein Fluge, Martin Maisenhølder, Stein Kvaløy, Harald Holte

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload